ES2754590T3 - An¿¢logos de compuestos de 4h-pirazolo[1,5-¿A]bencimidazol como inhibidores de las PARP - Google Patents
An¿¢logos de compuestos de 4h-pirazolo[1,5-¿A]bencimidazol como inhibidores de las PARP Download PDFInfo
- Publication number
- ES2754590T3 ES2754590T3 ES15777444T ES15777444T ES2754590T3 ES 2754590 T3 ES2754590 T3 ES 2754590T3 ES 15777444 T ES15777444 T ES 15777444T ES 15777444 T ES15777444 T ES 15777444T ES 2754590 T3 ES2754590 T3 ES 2754590T3
- Authority
- ES
- Spain
- Prior art keywords
- fluoro
- benzo
- imidazo
- carboxamide
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCN1CCC(*)CC1 Chemical compound CCN1CCC(*)CC1 0.000 description 14
- QEVQJKNWLKQVCR-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C)c1c(N)[n](-c(c(Br)cc(F)c2)c2Br)nc1OC)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C)c1c(N)[n](-c(c(Br)cc(F)c2)c2Br)nc1OC)=O QEVQJKNWLKQVCR-UHFFFAOYSA-N 0.000 description 1
- KYMCXQZOIHGJAV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C)c1c([nH]c2cc(F)cc(Br)c22)[n]2nc1C)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C)c1c([nH]c2cc(F)cc(Br)c22)[n]2nc1C)=O KYMCXQZOIHGJAV-UHFFFAOYSA-N 0.000 description 1
- YYCNOPLTMRZFEC-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1OC)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1OC)=O YYCNOPLTMRZFEC-UHFFFAOYSA-N 0.000 description 1
- VSLLBQBSHAGKLC-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(CC#N)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(CC#N)=O)=O VSLLBQBSHAGKLC-UHFFFAOYSA-N 0.000 description 1
- NQMSBAMXCWOLNV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c(cc1[nH]c2cc(F)c3)n[n]1c2c3Br)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c(cc1[nH]c2cc(F)c3)n[n]1c2c3Br)=O NQMSBAMXCWOLNV-UHFFFAOYSA-N 0.000 description 1
- IPVZGNDCJUXWMV-UHFFFAOYSA-N CC(C)(CN(C1)CC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1C)O Chemical compound CC(C)(CN(C1)CC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1C)O IPVZGNDCJUXWMV-UHFFFAOYSA-N 0.000 description 1
- RRHJAPMRYCRQAZ-UHFFFAOYSA-N CC(C)(CN(CC1)CCC1c1c([nH]c2c3c(C(N)=O)cc(F)c2)[n]3nc1)O Chemical compound CC(C)(CN(CC1)CCC1c1c([nH]c2c3c(C(N)=O)cc(F)c2)[n]3nc1)O RRHJAPMRYCRQAZ-UHFFFAOYSA-N 0.000 description 1
- DZLTZQJWWJRDIG-UHFFFAOYSA-N CC(C)CN(CC1)CCC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 Chemical compound CC(C)CN(CC1)CCC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 DZLTZQJWWJRDIG-UHFFFAOYSA-N 0.000 description 1
- MKTMZBIWWRJZKH-UHFFFAOYSA-N CC(C)N(CC1)CCC1(C)c1c([nH]c2c3c(C(N)=O)cc(F)c2)[n]3nc1OC Chemical compound CC(C)N(CC1)CCC1(C)c1c([nH]c2c3c(C(N)=O)cc(F)c2)[n]3nc1OC MKTMZBIWWRJZKH-UHFFFAOYSA-N 0.000 description 1
- OVYJJMLOWBOJDB-UHFFFAOYSA-N CC(C)N(CC1)CCC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 Chemical compound CC(C)N(CC1)CCC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 OVYJJMLOWBOJDB-UHFFFAOYSA-N 0.000 description 1
- SHPGECHVHGLCAM-UHFFFAOYSA-N CC1(CCN(CCOC)CC1)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 Chemical compound CC1(CCN(CCOC)CC1)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 SHPGECHVHGLCAM-UHFFFAOYSA-N 0.000 description 1
- ZGRIAFCYGNPFGU-UHFFFAOYSA-N CC1(CN(CC(F)(F)F)CC1)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 Chemical compound CC1(CN(CC(F)(F)F)CC1)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 ZGRIAFCYGNPFGU-UHFFFAOYSA-N 0.000 description 1
- NWBDARPJZPJEBC-UHFFFAOYSA-N CC1(CN(CC2CC2)CC1)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1C Chemical compound CC1(CN(CC2CC2)CC1)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1C NWBDARPJZPJEBC-UHFFFAOYSA-N 0.000 description 1
- SCEKCNTWKNPIPV-UHFFFAOYSA-N CC1(CN(CCS(C)(=O)=O)CC1)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 Chemical compound CC1(CN(CCS(C)(=O)=O)CC1)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 SCEKCNTWKNPIPV-UHFFFAOYSA-N 0.000 description 1
- UXJKYBPLTQNAFX-UHFFFAOYSA-N CCC(CC(CC1)C2)C1C(C)CC2c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 Chemical compound CCC(CC(CC1)C2)C1C(C)CC2c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 UXJKYBPLTQNAFX-UHFFFAOYSA-N 0.000 description 1
- QBQXRKGENOPPKW-UHFFFAOYSA-N CCC(CC1)(CCN1C(OC(C)(C)C)=O)C(C(OCC)=O)C#N Chemical compound CCC(CC1)(CCN1C(OC(C)(C)C)=O)C(C(OCC)=O)C#N QBQXRKGENOPPKW-UHFFFAOYSA-N 0.000 description 1
- RJIXLEQEDRMAAH-UHFFFAOYSA-N CCN(CC1)CC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 Chemical compound CCN(CC1)CC1(C)c1c([nH]c2cc(F)cc(C(N)=O)c22)[n]2nc1 RJIXLEQEDRMAAH-UHFFFAOYSA-N 0.000 description 1
- HTCZKIKMCWMUFP-UHFFFAOYSA-N CCN(CCC1)C1c1c([nH]c2c3c(C(N)=O)cc(F)c2)[n]3nc1 Chemical compound CCN(CCC1)C1c1c([nH]c2c3c(C(N)=O)cc(F)c2)[n]3nc1 HTCZKIKMCWMUFP-UHFFFAOYSA-N 0.000 description 1
- PXMBNSUKLTVWHM-UHFFFAOYSA-N CCOC(C(C1C(N2Cc3ccccc3)=O)=NNC1C2=O)=O Chemical compound CCOC(C(C1C(N2Cc3ccccc3)=O)=NNC1C2=O)=O PXMBNSUKLTVWHM-UHFFFAOYSA-N 0.000 description 1
- BQZKWFFYMCLGTN-UHFFFAOYSA-N CC[O](C)C(C1=CCN(Cc2ccccc2)C1)=O Chemical compound CC[O](C)C(C1=CCN(Cc2ccccc2)C1)=O BQZKWFFYMCLGTN-UHFFFAOYSA-N 0.000 description 1
- ZNVBOXQEGKNRSY-UHFFFAOYSA-N CNCc(cc1)ccc1-c1c([nH]c2c3c(C(N)=O)cc(F)c2)[n]3nc1 Chemical compound CNCc(cc1)ccc1-c1c([nH]c2c3c(C(N)=O)cc(F)c2)[n]3nc1 ZNVBOXQEGKNRSY-UHFFFAOYSA-N 0.000 description 1
- RMSONPHDUIEMKB-UHFFFAOYSA-N N#Cc1c([nH]c2cc(F)cc(Br)c22)[n]2nc1 Chemical compound N#Cc1c([nH]c2cc(F)cc(Br)c22)[n]2nc1 RMSONPHDUIEMKB-UHFFFAOYSA-N 0.000 description 1
- SYWPJGWIIQPORA-UHFFFAOYSA-N NC(c1c2[n]3ncc(C(CC4)CCN4C4CC4)c3[nH]c2cc(F)c1)=O Chemical compound NC(c1c2[n]3ncc(C(CC4)CCN4C4CC4)c3[nH]c2cc(F)c1)=O SYWPJGWIIQPORA-UHFFFAOYSA-N 0.000 description 1
- PLQWMLFNPGZOPC-UHFFFAOYSA-N NC(c1c2[n]3ncc(C4(CCN(CC5CC5)CC4)C#N)c3[nH]c2cc(F)c1)=O Chemical compound NC(c1c2[n]3ncc(C4(CCN(CC5CC5)CC4)C#N)c3[nH]c2cc(F)c1)=O PLQWMLFNPGZOPC-UHFFFAOYSA-N 0.000 description 1
- KDIVUVMUPAOTME-UHFFFAOYSA-N NC(c1c2[n]3ncc(C4(CCNCC4)C#N)c3[nH]c2cc(F)c1)=O Chemical compound NC(c1c2[n]3ncc(C4(CCNCC4)C#N)c3[nH]c2cc(F)c1)=O KDIVUVMUPAOTME-UHFFFAOYSA-N 0.000 description 1
- ZSHFGCWAZFLDPP-UHFFFAOYSA-N NC(c1c2[n]3ncc(C4CCNCC4)c3[nH]c2cc(F)c1)=O Chemical compound NC(c1c2[n]3ncc(C4CCNCC4)c3[nH]c2cc(F)c1)=O ZSHFGCWAZFLDPP-UHFFFAOYSA-N 0.000 description 1
- XIPKFXVJONLQKW-UHFFFAOYSA-N NC(c1cc(F)cc2c1[n]1nc(C3CCNCC3)cc1[nH]2)=O Chemical compound NC(c1cc(F)cc2c1[n]1nc(C3CCNCC3)cc1[nH]2)=O XIPKFXVJONLQKW-UHFFFAOYSA-N 0.000 description 1
- RFZUXWGKPKIJTF-UHFFFAOYSA-N NC(c1cc(F)cc2c1[n]1ncc(C3CCN(CCF)CC3)c1[nH]2)=O Chemical compound NC(c1cc(F)cc2c1[n]1ncc(C3CCN(CCF)CC3)c1[nH]2)=O RFZUXWGKPKIJTF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410144173.0A CN104974161B (zh) | 2014-04-10 | 2014-04-10 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
| CN201510113090 | 2015-03-13 | ||
| PCT/CN2015/075363 WO2015154630A1 (zh) | 2014-04-10 | 2015-03-30 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2754590T3 true ES2754590T3 (es) | 2020-04-20 |
Family
ID=54287319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15777444T Active ES2754590T3 (es) | 2014-04-10 | 2015-03-30 | An¿¢logos de compuestos de 4h-pirazolo[1,5-¿A]bencimidazol como inhibidores de las PARP |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9856262B2 (en:Method) |
| EP (1) | EP3130592B1 (en:Method) |
| JP (1) | JP6359175B2 (en:Method) |
| KR (1) | KR101921486B1 (en:Method) |
| CN (1) | CN106459057B (en:Method) |
| AU (1) | AU2015245786B2 (en:Method) |
| BR (1) | BR112016023397B1 (en:Method) |
| CA (1) | CA2944801C (en:Method) |
| DK (1) | DK3130592T3 (en:Method) |
| ES (1) | ES2754590T3 (en:Method) |
| HU (1) | HUE047410T2 (en:Method) |
| IL (1) | IL248258B (en:Method) |
| MX (1) | MX368496B (en:Method) |
| NZ (1) | NZ725165A (en:Method) |
| PL (1) | PL3130592T3 (en:Method) |
| PT (1) | PT3130592T (en:Method) |
| RU (1) | RU2672722C2 (en:Method) |
| SA (1) | SA516380051B1 (en:Method) |
| SG (1) | SG11201608438YA (en:Method) |
| TW (1) | TWI671301B (en:Method) |
| WO (1) | WO2015154630A1 (en:Method) |
| ZA (1) | ZA201607736B (en:Method) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974161B (zh) * | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
| CA3003122C (en) | 2015-09-30 | 2023-10-03 | Medshine Discovery Inc. | Salt type and crystal type of 4h-pyrazolo[1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| KR102596307B1 (ko) | 2017-04-27 | 2023-10-30 | 바이엘 애니멀 헬스 게엠베하 | 새로운 비시클릭 피라졸 유도체 |
| CN115028641B (zh) * | 2022-07-19 | 2024-05-28 | 湖南大学 | 一种钴催化合成5,8-双官能团取代咪唑并[1,2-a]吡嗪类化合物的方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025056690A1 (en) | 2023-09-12 | 2025-03-20 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Parp1- and immune-checkpoint inhibitors for the treatment of cancer patients overexpressing ubqln1 and/or ubqln4 |
| CN116969954B (zh) * | 2023-09-21 | 2023-11-28 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含内酰胺的三环稠合杂环化合物及其应用 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117534677B (zh) * | 2024-01-09 | 2024-03-12 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含亚胺的三环稠合杂环化合物及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916051A (en) * | 1987-04-07 | 1990-04-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| MY143499A (en) * | 2003-12-22 | 2011-05-31 | Sb Pharmco Inc | Crf receptor antagonist and methods relating thereto |
| WO2007076127A2 (en) | 2005-12-22 | 2007-07-05 | Biogen Idec Ma Inc | Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators |
| WO2007144669A1 (en) | 2006-06-15 | 2007-12-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp) |
| EP2069351B1 (en) * | 2006-06-20 | 2015-10-28 | AbbVie Inc. | Pyrazoloquinazolinones as parp inhibitors |
| GB0701273D0 (en) * | 2007-01-24 | 2007-02-28 | Angeletti P Ist Richerche Bio | New compounds |
| DK2656843T3 (en) | 2012-04-26 | 2015-04-20 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
| AU2013257018B2 (en) * | 2012-05-04 | 2017-02-16 | Merck Patent Gmbh | Pyrrolotriazinone derivatives |
| EP2666775A1 (en) * | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| CN104350056A (zh) | 2012-06-07 | 2015-02-11 | 霍夫曼-拉罗奇有限公司 | 端锚聚合酶的吡咯并嘧啶酮和吡咯并吡啶酮抑制剂 |
| ES2595240T3 (es) * | 2012-07-09 | 2016-12-28 | Lupin Limited | Derivados de tetrahidroquinazolinona como inhibidores de PARP |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| KR102083154B1 (ko) * | 2012-08-08 | 2020-03-02 | 메르크 파텐트 게엠베하 | （아자―）이소퀴놀리논 유도체 |
| CN104974161B (zh) | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
-
2015
- 2015-03-30 RU RU2016144202A patent/RU2672722C2/ru active
- 2015-03-30 WO PCT/CN2015/075363 patent/WO2015154630A1/zh not_active Ceased
- 2015-03-30 ES ES15777444T patent/ES2754590T3/es active Active
- 2015-03-30 PL PL15777444T patent/PL3130592T3/pl unknown
- 2015-03-30 CN CN201580017657.1A patent/CN106459057B/zh active Active
- 2015-03-30 BR BR112016023397-2A patent/BR112016023397B1/pt active IP Right Grant
- 2015-03-30 EP EP15777444.9A patent/EP3130592B1/en active Active
- 2015-03-30 PT PT157774449T patent/PT3130592T/pt unknown
- 2015-03-30 AU AU2015245786A patent/AU2015245786B2/en active Active
- 2015-03-30 JP JP2017504223A patent/JP6359175B2/ja active Active
- 2015-03-30 KR KR1020167031520A patent/KR101921486B1/ko active Active
- 2015-03-30 CA CA2944801A patent/CA2944801C/en active Active
- 2015-03-30 HU HUE15777444A patent/HUE047410T2/hu unknown
- 2015-03-30 US US15/302,588 patent/US9856262B2/en active Active
- 2015-03-30 MX MX2016013265A patent/MX368496B/es active IP Right Grant
- 2015-03-30 NZ NZ725165A patent/NZ725165A/en unknown
- 2015-03-30 SG SG11201608438YA patent/SG11201608438YA/en unknown
- 2015-03-30 DK DK15777444T patent/DK3130592T3/da active
- 2015-04-08 TW TW104111236A patent/TWI671301B/zh active
-
2016
- 2016-10-09 IL IL248258A patent/IL248258B/en active IP Right Grant
- 2016-10-10 SA SA516380051A patent/SA516380051B1/ar unknown
- 2016-11-09 ZA ZA2016/07736A patent/ZA201607736B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2754590T3 (es) | An¿¢logos de compuestos de 4h-pirazolo[1,5-¿A]bencimidazol como inhibidores de las PARP | |
| BR112021002772A2 (pt) | compostos, composições farmacêuticas, método de tratamento de câncer, métodos para regular a atividade de uma proteína, para inibir a proliferação de uma população de células, para tratar um distúrbio, para preparar uma proteína, para inibir metástase de tumor e para tratamento de câncer e usos | |
| CN103492384B (zh) | 作为trk抑制剂的化合物和组合物 | |
| TW202328124A (zh) | 1,4-氧雜氮雜環庚烷衍生物及其用途 | |
| TWI676622B (zh) | 作為rho激酶抑制劑的異喹啉磺醯衍生物 | |
| CN119585287A (zh) | Kras g12d蛋白水解靶向嵌合体 | |
| EP3935049A1 (en) | Carboxamide-pyrimidine derivatives as shp2 antagonists | |
| KR20260010430A (ko) | Kras g12s 및 g12c 억제제 | |
| CN104974161B (zh) | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 | |
| CN116888108A (zh) | 新型egfr降解剂 | |
| CN117693502A (zh) | 用于抑制或降解itk的化合物、包含其的组合物、其制备方法及其使用方法 | |
| WO2022134641A1 (zh) | 芳香杂环类化合物、药物组合物及其应用 | |
| RS65910B1 (sr) | Heterociklično jedinjenje | |
| CN105085525A (zh) | 作为rho激酶抑制剂的异喹啉磺酰衍生物 | |
| CN116057061A (zh) | Usp7抑制剂 | |
| WO2024097953A1 (en) | Naphthyridine compounds for inhibition of raf kinases | |
| TWI912370B (zh) | 芳香雜環類化合物、藥物組合物及其應用 | |
| HK40078733B (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| HK1229331B (zh) | 作为PARP抑制剂的4H-吡唑并[1，5-α]苯并咪唑化合物的类似物 | |
| WO2025185734A1 (zh) | 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途 | |
| BR112019017603A2 (pt) | Composto de tri-ciclo e aplicações do mesmo | |
| HK1261992B (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| HK1261992A1 (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| HK1229331A1 (en) | ANALOGUES OF 4H-PYRAZOLO[1,5-α]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS |